Carole Mitnick

Carole Mitnick, ScD, is Assistant Professor, Global Health & Social Medicine at Harvard Medical School, Associate Epidemiologist in the Division of Global Health Equity at Brigham & Women's Hospital, and Senior Research Fellow at Partners In Health. She has more than 10 years of experience in programmatic support, research, policy, and advocacy related to TB control, especially drug-resistant TB. She is supported by an NIAID career-development award to apply a novel epidemiologic method, which will limit bias in a comparison of treatment outcomes after non-random exposure to standardized or individualized treatment of MDR-TB in Peru. She is also funded by NIAID to develop a multi-site, randomized, clinical trial examining the potential for high-dose rifampin to shorten standard TB treatment. She is a founding member of a new initiative to improve treatment of drug-resistant TB through randomized controlled clinical trials (RESIST-TB).

Dr. Mitnick's particular areas of expertise are epidemiology, clinical outcomes research, clinical trials of MDR-TB and XDR-TB, and operational research. She is the lead author of sentinel papers published in the New England Journal of Medicine in 2003 and 2008 on clinical outcomes of individualized treatment for MDR-TB and XDR-TB in Peru and on a scientific advocacy piece on trials of MDR-TB treatment published in PLoS Medicine in 2007.

She actively participates in international groups, including: the Strategic and Technical Advisory Group to the WHO STOP-TB Department; INTERTB (aiming to develop TB clinical trials capacity in Latin America); the US CDC's Tuberculosis Trials Consortium task force on MDR-TB; the MDR-TB Working Group of the STOP-TB partnership and its research subgroup; the New Drugs Working Group and its Task Force on MDR-TB & XDR-TB; and the Research Advisory Group at Partners In Health.

She has worked extensively in Peru and performed program evaluations or GLC monitoring visits in Kazakhstan, Kyrgystan, Azerbaijan, Peru and the Democratic Republic of the Congo. She also serves as an ad hoc research resource to the GLC. She participated in the development of the Guidelines for the Programmatic Management of MDR-TB, as well as in the emergency update carried out in 2007.

Dr. Mitnick serves as a peer reviewer for The Lancet, the International Journal of Tuberculosis and Lung Disease, PLoS Medicine, Social Science and Medicine, Archives of Internal Medicine, Journal of Infectious Diseases, Clinical Infectious Diseases, Nature Reviews Microbiology, and the Scandinavian Journal of Infectious Diseases. She is an associate editor of the International Journal of Tuberculosis and Lung Disease

Dr. Mitnick holds a Doctor of Science in international health epidemiology and ecology from the Harvard School of Public Health. She is a native English speaker, has French fluency, and working Spanish.